Evaluation of the effectiveness of topical formulation of Falcaria vulgaris extract in patients with vitiligo
- Conditions
- Vitiligo.
- Registration Number
- IRCT20230930059569N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 36
Patients with mild to moderate vitiligo
Patients who have at least two symmetric skin lesions
Not suffering from skin diseases, such as allergies, etc.
Not suffering from light-sensitive diseases such as lupus and porphyria,
Not using photosensitizing drugs such as retinoids
Patients who have not received systemic treatment for vitiligo in the past one month and during this period
Patients with lesions that are homogeneous in terms of size, location, and duration of the lesion, and stable so that the lesion did not spread for at least the last 6 months.
Pregnancy and lactation
Patients with severe vitiligo
History of contact dermatitis
Having other skin diseases that affect the study
Patient dissatisfaction
Case of drug allergy
Face and axillary and inguinal region involvement
Mentally retarded patient
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The size of lesions. Timepoint: At the beginning of the study (before the start of the intervention) and 1, 2 and 3 months after the use of topical treatments. Method of measurement: Based on the Vitiligo Area Scoring Index - using the hand unit and the amount of depigmentation of the lesion.;Repigmentation percent. Timepoint: 1, 2 and 3 months after the use of topical treatments. Method of measurement: Observationally by comparing with the photograph of the lesion before starting the intervention.
- Secondary Outcome Measures
Name Time Method oticeability of lesions. Timepoint: At the end of the study (3 months after the beginning of the intervention). Method of measurement: Vitiligo Noticeability Scale.